Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Gastric05 first-line HER2-positive gastric/GEJ cancer trial
2024-513122-27-00Phase 3Authorised
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of trastuzumab deruxtecan, trastuzumab, pembrolizumab, capecitabine, fluorouracil and 2 more in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Progression-free survival. Planned start Jun 2025; status: authorised.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2024-513122-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513122-27-00.